-
[show abstract]
[hide abstract]
ABSTRACT: Course administration of ultralow doses of antibodies to S-100 protein restores cognitive functions and neurological status,
improves emotional state, and reduces anxiety in animals with modeled Alzheimer disease based on cholinergic system defi ciency
caused by subchronic treatment with scopolamine.
Bulletin of Experimental Biology and Medicine 05/2012; 148(3):533-535. · 0.27 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Kardos, a preparation containing ultralow doses of antibodies to C-terminal fragment of type 1 receptor of angiotensin II,
intragastrically administered to SHR rats with hereditary hypertension for 28 days reduced blood pressure by 14.8%. Kardos
was not inferior to losartan and, in contrast to the latter reduced HR by 9.4%.
Bulletin of Experimental Biology and Medicine 05/2012; 148(3):520-523. · 0.27 Impact Factor
-
K. V. Savel’eva,
M. V. Kachanova,
V. N. Pavlov,
R. A. Kazikhinurov,
M. Yu. Frolov,
A. B. Mukhin,
V. V. Udut,
Z. A. Yurmazov, Yu. L. Dugina,
S. A. Sergeeva,
O. I. Epshtein
[show abstract]
[hide abstract]
ABSTRACT: The use of afala in patients with benign prostatic hyperplasia and moderate urination disturbances reduced the symptoms of
the disease, improved urodynamic parameters, and increased quality of life. Clinical efficiency of afala was comparable with
the efficiency of Serenoa repens extract (reference preparation).
Bulletin of Experimental Biology and Medicine 04/2012; 148(2):305-307. · 0.27 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Chronic treatment of rats with kardosten for 6 months had a positive effect on some ECG values and behavior without disordering the hepatorenal functions. All effects of the drug observed during a course of treatment were leveled and the parameters reached the basal values within 2 weeks after drug discontinuation, this confirming its safety.
Bulletin of Experimental Biology and Medicine 12/2010; 150(2):215-8. · 0.27 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: We studied the effects of preliminary administration of haloperidol in low doses on changes in motor activity of edible snail and in electrical properties of defensive behavior command neurons induced by chronic administration of haloperidol. The rate of locomotion decreased after injections of haloperidol preparations (C6, C12, C30, C200 and a mixture C12+C30+C200) for 3 days. Similar changes were observed after 3 days of haloperidol administration. Haloperidol preparations in low doses produced a modulating effect on the decrease in locomotion rate and hyperpolarization of command neurons in edible snails caused by chronic exposure to haloperidol: the decrease in locomotion rate caused by chronic haloperidol treatment was prevented by preliminary injection of haloperidol in low doses C6, C12 and C30; the depolarizing shift of command neuron membrane potential was also abolished after consecutive injection of the same haloperidol preparations C6, C12 and C30.
Bulletin of Experimental Biology and Medicine 11/2009; 148(5):754-7. · 0.27 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The antiamnestic effects of tenoten (pediatric formulation) was demonstrated on the model of scopolamine-induced amnesia of passive avoidance reflex and the nootropic effect of this preparation was demonstrated on the model of incomplete conditioning and in rat pups with experimental attention deficit syndrome. The efficiency of the preparation was comparable to that of piracetam and phenibut and even surpassed it by some parameters.
Bulletin of Experimental Biology and Medicine 09/2009; 148(3):524-6. · 0.27 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Experiments on rats demonstrated antiaggressive activity of ultralow doses of antibodies to S-100 protein in tests of motivated and unmotivated aggression. The effect of ultralow doses of antibodies to S-100 protein in single and course treatment was not inferior to that of benzodiazepine anxiolytic diazepam.
Bulletin of Experimental Biology and Medicine 09/2009; 148(3):527-9. · 0.27 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Ultralow doses of antibodies to S-100 protein increased rat survival, reduced neurological deficit, eliminated myorelaxation, and improved movement coordination and cognitive functions in rats with experimental hemorrhagic stroke; the efficiency of the preparation was not inferior to that of nimodipine. In contrast to nimodipine, ultralow doses of antibodies to S-100 protein exhibited pronounced anxiolytic properties.
Bulletin of Experimental Biology and Medicine 09/2009; 148(3):530-2. · 0.27 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Course administration of ultralow doses of antibodies to S-100 protein restores cognitive functions and neurological status, improves emotional state, and reduces anxiety in animals with modeled Alzheimer disease based on cholinergic system deficiency caused by subchronic treatment with scopolamine.
Bulletin of Experimental Biology and Medicine 09/2009; 148(3):533-5. · 0.27 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: In patients with rheumatoid arthritis, prolongation of artrofoon therapy to 2 years led to maintenance of the positive clinical effect attained after 6-month treatment. Moreover, significant improvement was observed by some parameters (integral pain intensity, swelling index, Ritchie articular index, morning stiffness, and articular score). No side effects related to artrofoon treatment were observed throughout the treatment period in the main group. The results indicate high efficiency and good tolerability of the preparation and attest to advisability of its long-term use.
Bulletin of Experimental Biology and Medicine 09/2009; 148(3):486-8. · 0.27 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Experiment on ISIAH rats showed that antibodies to endothelial NO synthase in ultralow doses (impaza) produced a mild and progressive antihypertensive effect slightly inferior to that of losartan. The use of impaza is perspective in patients with erectile dysfunction and cardiovascular pathology.
Bulletin of Experimental Biology and Medicine 09/2009; 148(3):518-9. · 0.27 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Screening of three potential antiulcer preparations containing ultralow doses of antibodies to endogenous regulators of ulcer formation (gastrin, histamine, and H2 histamine receptors) on the model of acetic acid-induced gastric ulcer in rats revealed pronounced antiulcer effect of ultralow doses of antibodies to histamine. The dynamics of regeneration of the ulcer focus by morphological and histological characteristics was similar during treatment with ultralow doses of antibodies to histamine and with famotidine.
Bulletin of Experimental Biology and Medicine 09/2009; 148(3):540-2. · 0.27 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Kardos, a preparation containing ultralow doses of antibodies to C-terminal fragment of type 1 receptor of angiotensin II, intragastrically administered to SHR rats with hereditary hypertension for 28 days reduced blood pressure by 14.8%. Kardos was not inferior to losartan and, in contrast to the latter reduced HR by 9.4%.
Bulletin of Experimental Biology and Medicine 09/2009; 148(3):520-3. · 0.27 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Comparative placebo-controlled clinical trials on the efficiency and safety of ultralow doses of antibodies to human IFN-gamma (anaferon pediatric formulation and anaferon) and prophylaxis of bacterial complication showed that administration of these preparations in complex therapy of bacterial infection reduced the incidence of bacterial complications of viral infections and considerably decreased the duration of the main clinical symptoms of the disease.
Bulletin of Experimental Biology and Medicine 08/2009; 148(2):295-6. · 0.27 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The safety of combined administration of ultralow doses of antigens to endothelial NO synthase (impaza) and nitrates for the treatment of erectile dysfunction in CHD patients was evaluated in an open non-comparative clinical trial. The efficiency and safety of impaza and the possibility of its administration to patients receiving nitrates were demonstrated.
Bulletin of Experimental Biology and Medicine 08/2009; 148(2):325-7. · 0.27 Impact Factor
-
K V Savel'eva,
M V Kachanova,
V N Pavlov,
R A Kazikhinurov,
M Yu Frolov,
A B Mukhin,
V V Udut,
Z A Yurmazov, Yu L Dugina,
S A Sergeeva,
O I Epshtein
[show abstract]
[hide abstract]
ABSTRACT: The use of afala in patients with benign prostatic hyperplasia and moderate urination disturbances reduced the symptoms of the disease, improved urodynamic parameters, and increased quality of life. Clinical efficiency of afala was comparable with the efficiency of Serenoa repens extract (reference preparation).
Bulletin of Experimental Biology and Medicine 08/2009; 148(2):305-7. · 0.27 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The involvement of the GABA-B neurotransmitter system in the realization of anxiolytic and antidepressant activities of ultralow-dose antibodies to S-100 protein is demonstrated. Simultaneous injection of ultralow-dose antibodies to S-100 protein and GABA-B receptor agonist baclofen reduced the anxiolytic and antidepressant effects of the drug, while GABA-B receptor antagonist faclofen stimulated the anxiolytic and reduced the antidepressant effect of ultralow-dose antibodies to S-100 protein. The effect of ultralow-dose antibodies to S-100 protein on the GABA-B-ergic system differs from that of benzodiazepine anxiolytics (diazepam) and tricyclic antidepressants (amitryptiline) not affecting this transmitter system.
Bulletin of Experimental Biology and Medicine 06/2008; 145(5):614-6. · 0.27 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The involvement of the serotoninergic system in the realization of anxiolytic and antidepressant activities of antibodies to S-100 protein in ultralow doses is proven. Administration of ultralow-dose antibodies to S-100 protein in combination with serotoninergic agents (ketanserin and 5-hydroxytryptophan) reduced the anxiolytic and antidepressant effects of antibodies.
Bulletin of Experimental Biology and Medicine 06/2007; 143(5):598-600. · 0.27 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Proproten (ultralow doses of antibodies to S100 protein) exhibited neuroprotective activity in rats with experimental photochemical thrombosis of the prefrontal cortex. Proproten was more potent than standard neuroprotectors piracetam and vinpocetine in alleviating the signs of memory disorders produced by ischemic injury. Pathomorphological study of the damaged area confirmed the neuroprotective effect of Proproten.
Bulletin of Experimental Biology and Medicine 05/2005; 139(4):404-7. · 0.27 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: We studied the effects of antibodies against interferon-gamma, erythropoietin, and tumor necrosis factor-alpha in ultralow doses on the production of endogenous interferon-gamma. Course peroral treatment with potentiated antibodies to interferon-gamma in various dilutions produced similar changes in experimental animals. The treatment stimulated spontaneous production of endogenous interferon-gamma by mouse lymphocytes. It should be emphasized that antibodies to other cytokines in ultralow doses did not stimulate interferon-gamma production. These data illustrate the specificity of action of antibodies to endogenous regulators in ultralow doses.
Bulletin of Experimental Biology and Medicine 06/2004; 137(5):460-2. · 0.27 Impact Factor